Ranked #960 of 8,699 institutional investors
Frazier Life Sciences Management, L.P.
Palo Alto, CA
$3.93B
US stock portfolio at live prices · today +$35.4M (+0.91%)
Market closed. Prices as of Nov 20, 7:41 AM ET
- Value at quarter end (Q3 2026)
- $4.03B
- Change from Q2 2026
- −$561.5M (−12.23%)
- Positions
- 40 · 5 new, 2 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$523M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesMIRM 18.7%ERAS 10.7%MBX 9.04%ARQT 6.82%MAZE 4.36%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals, Inc. | 7,679,684 | $733M | 18.7% | Unchanged |
| ERAS Erasca, Inc. | 29,475,188 | $419M | 10.7% | Added +18% |
| MBX MBX Biosciences, Inc. | 6,652,013 | $355M | 9.04% | Unchanged |
| ARQT Arcutis Biotherapeutics, Inc. | 9,874,511 | $268M | 6.82% | Unchanged |
| MAZE Maze Therapeutics, Inc. | 5,282,915 | $171M | 4.36% | Added +5% |
| TRVI Trevi Therapeutics, Inc. | 9,539,147 | $131M | 3.33% | Reduced −4% |
| PVLA Palvella Therapeutics, Inc. | 882,400 | $129M | 3.27% | Unchanged |
| KRYS Krystal Biotech, Inc. | 391,319 | $124M | 3.14% | Reduced −19% |
| ATTO Attovia Therapeutics, Inc. | 7,046,271 | $110M | 2.79% | New |
| BRVE Braveheart Bio, Inc. | 5,267,321 | $102M | 2.58% | New |
| IRON Disc Medicine, Inc. | 934,852 | $71.2M | 1.81% | Reduced −31% |
| PBLS Parabilis Medicines, Inc. | 2,330,750 | $64.4M | 1.64% | Added +21% |
| PHAT Phathom Pharmaceuticals, Inc. | 12,466,489 | $63.3M | 1.61% | Unchanged |
| MNKD MannKind Corporation | 15,755,491 | $62.2M | 1.58% | Added +139% |
| DYN Dyne Therapeutics, Inc. | 3,853,082 | $61.8M | 1.57% | Added +22% |
| TARS Tarsus Pharmaceuticals, Inc. | 720,338 | $55.9M | 1.42% | Reduced −1% |
| VOR Vor Biopharma Inc. | 2,743,939 | $50.8M | 1.29% | Added +8% |
| AURA Aura Biosciences, Inc. | 7,100,000 | $49.6M | 1.26% | Unchanged |
| QUIT Achieve Life Sciences, Inc. | 7,614,836 | $44.7M | 1.14% | Unchanged |
| ZLAB Zai Lab Limited | 1,902,320 | $41.7M | 1.06% | Unchanged |
| ACRS Aclaris Therapeutics, Inc. | 8,729,516 | $30.6M | 0.78% | Added +77% |
| BCRX BioCryst Pharmaceuticals, Inc. | 4,009,240 | $29.3M | 0.75% | Unchanged |
| ACAD Acadia Pharmaceuticals Inc. | 1,438,198 | $25.3M | 0.64% | Unchanged |
| CLDX Celldex Therapeutics, Inc. | 900,080 | $25.2M | 0.64% | New |
| IMCR Immunocore Holdings plc | 829,752 | $22.1M | 0.56% | Added +71% |
| EOLS Evolus, Inc. | 2,630,665 | $18.4M | 0.47% | Unchanged |
| STTK Shattuck Labs, Inc. | 3,750,000 | $17.1M | 0.43% | Unchanged |
| DSGN Design Therapeutics, Inc. | 1,809,854 | $16.9M | 0.43% | Unchanged |
| RLAY Relay Therapeutics, Inc. | 1,015,693 | $16.2M | 0.41% | Unchanged |
| SRPT Sarepta Therapeutics, Inc. | 1,069,959 | $15.2M | 0.39% | New |
| ALLO Allogene Therapeutics, Inc. | 22,446,668 | $15.0M | 0.38% | Unchanged |
| LXEO Lexeo Therapeutics, Inc. | 4,824,725 | $14.2M | 0.36% | Unchanged |
| KLRA Kailera Therapeutics, Inc. | 1,200,000 | $13.9M | 0.35% | Added +9% |
| VALN Valneva SE | 2,291,666 | $12.3M | 0.31% | Unchanged |
| GLUE Monte Rosa Therapeutics, Inc. | 1,000,000 | $8.9M | 0.23% | Unchanged |
| SVRA Savara Inc. | 1,113,752 | $5.8M | 0.15% | Reduced −89% |
| ORIC ORIC Pharmaceuticals, Inc. | 751,672 | $5.8M | 0.15% | New |
| AUTL Autolus Therapeutics plc | 4,447,910 | $4.4M | 0.11% | Unchanged |
| XLO Xilio Therapeutics, Inc. | 422,505 | $3.2M | <0.1% | Unchanged |
| IBIO iBio, Inc. | 1,953,467 | $1.6M | <0.1% | Unchanged |